Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 12/20 | 0.59 |
| ▸ | QDPR | P09417 | 1/20 | 0.56 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.47 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.47 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4881862 | 0.98 | HTR2C (0.61) | HTR2CQDPRSLC18A3SIGMAR1TLR9 | |
| SCHEMBL8640763 | 0.89 | HTR3A (0.55) | HTR2CQDPR | |
| SCHEMBL2884802 | 0.85 | HTR2C (0.46) | HTR2CQDPR | |
| SCHEMBL5584982 | 0.83 | SLC6A2 (0.58) | HTR2CQDPRSLC18A3SIGMAR1TLR9 | |
| SCHEMBL5584693 | 0.83 | HTR2C (0.54) | HTR2CQDPRSLC18A3SIGMAR1TLR9 | |
| SCHEMBL17395615 | 0.83 | QDPR (0.71) | HTR2CQDPRSLC18A3SIGMAR1TLR9 | |
| SCHEMBL31328458 | 0.83 | QDPR (0.71) | HTR2CQDPRSLC18A3SIGMAR1TLR9 | |
| SCHEMBL2708481 | 0.83 | HTR2C (0.54) | HTR2CQDPRSLC18A3SIGMAR1TLR9 | |
| SCHEMBL5585044 | 0.83 | SLC6A2 (0.58) | HTR2CQDPRSLC18A3SIGMAR1TLR9 | |
| SCHEMBL31223098 | 0.83 | HTR2C (0.54) | HTR2CQDPRSLC18A3SIGMAR1TLR9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020257180-A1 | AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC (US) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020231806-A1 | PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC (US) | 2020-11-19 | — | — | WO | disclosed |
| EP-3164395-B1 | INDANE AND INDOLINE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | NOVARTIS AG (CH) | 2019-03-27 | — | — | EP | disclosed |
| WO-2014193932-A1 | PYRROLOTRIAZINES AS ALK INHIBITORS | CEPHALON, INC. (US) | 2014-12-04 | — | — | WO | disclosed |
| EP-1930319-B1 | Proline derivatives and use thereof as drugs | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-20080312271-A1 | AZABENZIMIDAZOLYL COMPOUNDS | PFIZER INC. | 2008-12-18 | — | — | US | disclosed |
| US-20080280933-A1 | BENZIMIDAZOLYL COMPOUNDS | EFREMOV IVAN | 2008-11-13 | — | — | US | disclosed |
| EP-1308439-B1 | PROLINE DERIVATIVES AND USE THEREOF AS DRUGS | MITSUBISHI TANABE PHARMA CORP (JP) | 2008-10-15 | — | — | EP | disclosed |
| EP-1950199-A1 | Proline derivatives and use thereof as drugs | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-07-30 | — | — | EP | disclosed |
| EP-1930319-A1 | Proline derivatives and use thereof as drugs | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-06-11 | — | — | EP | disclosed |
| US-7060722-B2 | Proline derivatives and use thereof as drugs | MITSUBISHI PHARMA CORPORATION (JP) | 2006-06-13 | — | — | US | disclosed |
| US-20050245538-A1 | Proline derivatives and use thereof as drugs | KITAJIMA HIROSHI | 2005-11-03 | — | — | US | disclosed |
| EP-1188747-B1 | PHENOXYPROPYLAMINE COMPOUNDS | MITSUBISHI PHARMA CORP (JP) | 2005-09-07 | — | — | EP | disclosed |
| US-20040138227-A1 | Phenoxypropylamine compounds | NISHIYAMA AKIRA | 2004-07-15 | — | — | US | disclosed |
| US-20040106655-A1 | Proline derivatives and the use thereof as drugs | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2004-06-03 | — | — | US | disclosed |
| US-6720320-B2 | ANTISEROTONINE AGENTS | MITSUBISHI PHARMA CORPORATION (JP) | 2004-04-13 | — | — | US | disclosed |
| EP-1308439-A1 | PROLINE DERIVATIVES AND USE THEREOF AS DRUGS | WELFIDE CORPORATION (JP) | 2003-05-07 | — | — | EP | disclosed |
| US-20020111358-A1 | Phenoxypropylamine compounds | MITSUBISHI PHARMA CORPORATION (JP) | 2002-08-15 | — | — | US | disclosed |
| EP-1188747-A1 | PHENOXYPROPYLAMINE COMPOUNDS | Mitsubishi Pharma Corporation (JP) | 2002-03-20 | — | — | EP | disclosed |
| US-4188396-A | ANTIDEPRESSANTS | CIBA-GEIGY CORPORATION (US) | 1980-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138227-A1 | Phenoxypropylamine compounds | HTR1A, HTR1D, HTR5A | HTR2C 9/4885QDPR 214/4885SLC18A3 162/4885 |
| US-20080280933-A1 | BENZIMIDAZOLYL COMPOUNDS | PAICS, TMBIM6, ABCG2 | HTR2C 575/4885QDPR 116/4885SLC18A3 1341/4885 |
| US-20050245538-A1 | Proline derivatives and use thereof as drugs | DPP4, DPP3, DPP7 | HTR2C 2119/4885QDPR 66/4885SLC18A3 1573/4885 |
| US-20040106655-A1 | Proline derivatives and the use thereof as drugs | DPP4, DPP3, DPP7 | HTR2C 1460/4885QDPR 102/4885SLC18A3 1575/4885 |
| US-20080312271-A1 | AZABENZIMIDAZOLYL COMPOUNDS | AZI2, PAICS, UGT2B7 | HTR2C 465/4885QDPR 74/4885SLC18A3 1289/4885 |
| US-20020111358-A1 | Phenoxypropylamine compounds | HTR1A, HTR1D, HTR5A | HTR2C 9/4885QDPR 214/4885SLC18A3 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.